No products in the cart
BPC-157 peptides are Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
What is BPC-157?
BPC-157, which stands for Body Protection Compound-157, is obtained from the parent protein known as body protection compound (BPC). BPC is a naturally occurring protein in human digestive tract. Research suggests that it protects the gastrointestinal tract lining from damage, mediates healing, and encourages the growth of blood vessels. BPC 157 is a penta-decapeptide made up of 15 amino acids. It is derived from a stretch of the body protection compound (BPC) discovered and purified from human gastric juice. Animal studies have observed its potential efficacy in healing different wounds such as muscle, tendon, and torn ligaments. It may further protect organs and help to prevent gastric ulcers. Sikiric et al noted that there was a strong protection, noted following intragastric or intraperitoneal administration of BPC 157. BPC-157 also has the potential to enhance the health of the digestive tract and prevent against irritable bowel syndrome (IBS), gastrointestinal cramps, and Crohn’s disease. The peptide also has analgesic properties, and by promoting the blood flow to the damaged tissues, it may help heal skin burns faster.
The synthetic peptide appears to have retained several of the healing properties of its parent molecule, such as:
– Blood vessel growth
– Wound healing
– Nitric oxide generation
– Immune system function
– The coagulation cascade
– Gene expression
– Hormone regulation (specifically in the gastrointestinal, nervous system)
AKA: BPC 157
Molecular Formula: C62H98N16O22
Molecular Weight: 1419.5355 g/mol
Sequence: L-Valine,glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-Lprolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-;glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyllysyl-L-prolyl-L-alanyl-L- alpha-aspartylL-alpha-aspartyl-L-alanylglycyl-L-leucyl-L-valine
PubChem: CID 108101
BPC-157 Peptide Research
BPC-157 and Wound Healing
The mucosal barrier in the GI tract helps to protect the underlying tissues from the harmful actions of bile, gastric acid, and other compounds necessary for digestion and absorption of nutrients from food. BPC-157 is believed to help preserve the structural integrity of the mucosal layer. The role is partially mediated through the recruitment of fibroblasts. Fibroblasts are pivotal to healing wounds as they produce extracellular matrix proteins such as fibrin, collagen, elastin, and others. BPC-157 has been observed to promote proliferation and faster migration of fibroblasts in dose-dependent manner, both in culture and in vivo.
BPC-157 and Vascular Growth and Collateralization
The peptide has the potential to be a powerful angiogenic and studies suggest it may enhance endothelial cells’ growth and proliferation, which line the walls of blood vessels. Research in rats has observed that the peptide may substantially increase the collateral blood vessel growth rate in the setting of ischemia. The above effect has been majorly observed in the GI tract, but research has noted similar observations in muscle, neurological, and cardiovascular tissues. Thus, the findings highlight the potential of BPC-157 to be used for the treatment of stroke and heart attack and a probative molecule for understanding the healing process post-ischemic injury. Research using chicken embryos has posited that BPC-157 may also have the potential to promote vascular growth through activation of VEGFR2 pathway. VEGFR2 is a cell surface receptor active in the nitric oxide signaling and helps in cell growth, longevity, and proliferation. BPC-157 treatment may promote vascular “running” in cultured cells. Vascular “running” is the growth and development of new blood vessels towards a site of injury or around the area of blood clot to reach out to distal tissues and thus protect cellular function. This function of BPC-157 has the potential to be used to replace unwanted surgical interventions such as coronary artery bypassing, stenting, and more which a simple and effective oral medication for the slow-progressing vascular occlusions like in atherosclerotic cardiac conditions.
BPC-157 and Tendon Healing
BPC-157 studies have so far observed positive effects in connective tissue healing such as ligament, bone, and tendon. Ligament and tendon injuries take a long time to heal due to the poor blood supply to these tissues. There is slower migration of fibroblasts and wound-healing cells to these sites of injury owing to poor blood supply, and therefore the repair process is obstructed. The peptide has the potential to improve collateralization and density of fibroblasts in the sites of injury in research involving rat tendons. Experimental research has found BPC-157 to be more beneficial than treatment using EFG, bFGF, and VGF hormones. Immunostaining assays involving FITC conjugated phalloidin have observed BPC-157 enhance F-actin formation in fibroblasts. F-actin is crucial for cell structure and function and promotes cell migration. Immunoblotting experiments have noted that BPC-157 appears to increase phosphorylation of paxillin and FAK proteins which are crucial for cellular migration.
BPC-157 and antioxidant properties
Studies in rat models have noted the BPC-157 appears to have antioxidant properties and may help to neutralize oxidative stress molecules like nitric oxide and malondialdehyde (MDA) and reactive oxygen species in the GI tract. Research further hypothosizes that modified Lactococcus lactis bacteria may increase the amount of the peptide in cell culture and can possibly deliver it to the GI tract.
BPC-157 and Drug Side Effects
The clinical use of a pharmaceutical molecule is restricted by its potential side effects. Ibuprofen and other NSAIDs, for instance, cannot be consumed over a long span as they increase the risk of gastric bleeding and cardiac arrest. BPC-157 has been suggested as a potential treatment to overcome the adverse effects of NSAIDs, medications used in psychiatric conditions, and a number of cardiac medications.
The peptide has the potential to work against the side effects of various drugs on not only the GI tract but on brain, heart and other tissues as well. BPC-157 research has observed the peptide’s protective potential against the prolongation of QTc in the hearts in rats. Prolonged QTc can lead to fatal arrhythmias. QTc prolongation is a side effect of drugs used to treat diabetes, schizophrenia, and other psychiatric conditions. Similarly, BPC-157 may also overcome catalepsy and somatosensory disturbance. This helps treat difficult psychiatric conditions as patients tend to discontinue the treatment due to severe side effects.
BPC-157 and Bees
Colony collapse disorder (CCD) is a syndrome that causes entire colonies of bees to decline rapidly and die entirely, possibly due to Nosema ceranae fungal infection in the GI tract of bees. Experimental use of BPC-157 along with bee food noted significant improvement of the bee GI tract and hive survival.In this research, the peptide was successful for oral use in natural field settings to reduce the effect of CCD on bees which is the natural pollinator of many crop plants.
BPC-157 is being actively studied in a number of cell culture and animal models. The peptide not only has the potential to assist in wound healing and vascular growth but also to study the regulation of these processes, especially in angiogenesis which is extremely crucial in wound healing, cancer progression, and embryo development. BPC-157 studies have reported minimal adverse effects, medium oral, and excellent subcutaneous bioavailability in mice. The dosage in mice (per kg) does not scale up to humans.
- Jelovac, N., Sikirić, P., Rucman, R., Petek, M., Perović, D., Konjevoda, P., Marović, A., Seiwerth, S., Grabarević, Z., Sumajstorcić, J., Dodig, G., & Perić, J. (1998). A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine. Biological psychiatry, 43(7), 511–519. https://doi.org/10.1016/s0006-3223(97)00277-1
- Sikirić, P., Mazul, B., Seiwerth, S., Grabarević, Z., Rucman, R., Petek, M., Jagić, V., Turković, B., Rotkvić, I., Mise, S., Zoricić, I., Jurina, L., Konjevoda, P., Hanzevacki, M., Gjurasin, M., Separović, J., Ljubanović, D., Artuković, B., Bratulić, M., Tisljar, M., … Sumajstorcić, J. (1997). Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress. Digestive diseases and sciences, 42(3), 661–671. https://doi.org/10.1023/a:1018880000644
- Tkalcević, V. I., Cuzić, S., Brajsa, K., Mildner, B., Bokulić, A., Situm, K., Perović, D., Glojnarić, I., & Parnham, M. J. (2007). Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. European journal of pharmacology, 570(1-3), 212–221. https://doi.org/10.1016/j.ejphar.2007.05.072
- Hsieh, M. J., Liu, H. T., Wang, C. N., Huang, H. Y., Lin, Y., Ko, Y. S., Wang, J. S., Chang, V. H., & Pang, J. S. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of molecular medicine (Berlin, Germany), 95(3), 323–333. https://doi.org/10.1007/s00109-016-1488-y
- Chang, C. H., Tsai, W. C., Lin, M. S., Hsu, Y. H., & Pang, J. H. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of applied physiology (Bethesda, Md. : 1985), 110(3), 774–780. https://doi.org/10.1152/japplphysiol.00945.2010
- Škrlec, K., Ručman, R., Jarc, E., Sikirić, P., Švajger, U., Petan, T., Perišić Nanut, M., Štrukelj, B., & Berlec, A. (2018). Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities. Applied microbiology and biotechnology, 102(23), 10103–10117. https://doi.org/10.1007/s00253-018-9333-6
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.